한글목차

세계의 바이오의약품 업계에 대해 조사분석했으며, 2016-2025년 자가면역 공동 연구·라이선싱 계약 943건에 관한 계약 조건 등의 상세 데이터를 제공하고 있습니다.

목차

개요

제1장 서론

제2장 자가면역 계약의 동향

• 서론
• 과거 수년간 자가면역 계약
• 자가면역 계약 : 계약 유형별
• 자가면역 계약 : 산업 부문별
• 자가면역 계약 : 개발 단계별
• 자가면역 계약 : 기술 유형별

제3장 자가면역 계약에 관한 재무적 계약 조건

• 서론
• 자가면역 계약에 관한 공개된 재무 조건
• 자가면역 계약 헤드라인 금액
• 자가면역 계약 선불
• 자가면역 계약 마일스톤 지불
• 자가면역 계약 로열티율

제4장 주요 자가면역 교섭자와 계약

• 서론
• 자가면역 계약에서 가장 활발
• 자가면역 분야에서 가장 활발한 교섭자 리스트
• 상위 자가면역 계약(금액)

제5장 자가면역 계약 문서 디렉토리

• 서론
• 계약서가 입수 가능한 자가면역 파트너 계약

제6장 자가면역 계약 : 치료 표적별

• 서론
• 계약 : 자가면역 치료 표적별
• 계약 디렉토리
• 계약 디렉토리 - 자가면역 계약 : 기업별(A-Z)(2016-2025년)
• 계약 디렉토리 - 자가면역 계약 : 기술 유형별(2016-2025년)
• 계약 유형의 정의
• Biopharma Research Ltd 소개
• Current Partnering
• Current Agreements
• Current Partnering으로부터의 최근 리포트 타이틀

영문목차

Autoimmune Collaboration and Licensing Deals provides a comprehensive understanding and unprecedented access to the autoimmune deals entered into by the worlds leading biopharma companies.

Fully revised and updated, the report provides details of 943 autoimmune deals from 2016 to 2025.

The report includes coverage of the following autoimmune diseases:

• Multiple sclerosis, Restless leg syndrome, Dermatitis, Eczema, Alopecia, Psoriasis, Celiac disease, Inflammatory bowel disease, Crohn's disease, Ulcerative colitis, Glomerulonephritis, Endometriosis, Immune thrombocytopenic purpura, Neutropenia, Graft versus host disease, Scleroderma, Systemic lupus erythematosus, Addison's disease, Diabetes Type 1, Ankylosing spondylitis, Juvenile arthritis, Psoriatic arthritis, Rheumatoid arthritis, Uveitis, Narcolepsy, Chronic obstructive pulmonary disease, Idiopathic pulmonary fibrosis, Sarcoidosis, Meniere's disease, and other autoimmune disorders.
• The report provides access to deal payment terms as announced between the parties. This data provides useful insight into the payment and other deal terms.
• Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered and rights transferred - contract documents provide this insight where press releases and databases do not.
• This report contains a comprehensive listing of collaboration and licensing deals announced since 2016 as recorded in the Current Agreements deals and alliances database, including financial terms where available, plus links to online copies of actual licensing contract documents as submitted to the Securities Exchange Commission by companies and their partners.
• The initial chapters of this report provide an orientation of autoimmune dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an analysis of the trends in autoimmune dealmaking.
• Chapter 3 covers the financial deal terms for deals signed in the autoimmune field with stage of development announced. Deals are listed and sectioned by headline value, upfront payment, milestone payment and royalty rates.
• Chapter 4 provides a review of the top 25 most active biopharma companies in autoimmune dealmaking. Where the deal has an agreement contract published at the SEC a link provides online access to the contract via the Current Agreements deals and alliances database.
• Chapter 5 provides a comprehensive and detailed review of autoimmune deals signed and announced since 2016 where a contract document is available. Each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
• Chapter 6 provides a comprehensive directory of autoimmune deals listed by theraeutic target.
• The report also includes numerous table and figures that illustrate the trends and activities in autoimmune deal making since 2016.
• In addition, a comprehensive deal directory is provided organized by company A-Z and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Key benefits

Autoimmune Collaboration and Licensing Deals provides the reader with the following key benefits:

• Understand deal trends since 2016
• Browse autoimmune collaboration and licensing deals
• Benchmark analysis - identify market value of transactions
• Financials terms - upfront, milestone, royalties
• Directory of deals by company A-Z, therapy focus and technology type
• Leading deals by value
• Most active dealmakers
• Identify assets and deal terms for each transaction
• Access contract documents - insights into deal structures
• Due diligence - assess suitability of your proposed deal terms for partner companies
• Save hundreds of hours of research time

Report scope

• Autoimmune Collaboration and Licensing Deals is intended to provide the reader with an in-depth understanding of autoimmune trends and structure of deals entered into by leading biopharma companies worldwide.

Autoimmune Collaboration and Licensing Deals includes:

• Trends in autoimmune dealmaking in the biopharma industry
• Overview of collaboration and licensing deal structure
• Directory of autoimmune deal records covering pharmaceutical and biotechnology
• The leading autoimmune deals by value
• Most active autoimmune licensing dealmakers

In Autoimmune Collaboration and Licensing Deals, the available deals are listed by:

• Company A-Z
• Headline value
• Therapeutic area
• Technology type
• Each deal title links via Weblink to an online version of the actual deal record, providing easy access to each contract document where available.
• Autoimmune Collaboration and Licensing Deals provides comprehensive access to available records for deals, including contract documents where available.

Analyzing contract agreements allows due diligence of:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in autoimmune dealmaking

• 2.1. Introduction
• 2.2. Autoimmune deals over the years
• 2.3. Autoimmune deals by deal type
• 2.4. Autoimmune deals by industry sector
• 2.5. Autoimmune deals by stage of development
• 2.6. Autoimmune deals by technology type

Chapter 3 - Financial deal terms for autoimmune deals

• 3.1. Introduction
• 3.2. Disclosed financials terms for autoimmune deals
• 3.3. Autoimmune deal headline values
• 3.4. Autoimmune deal upfront payments
• 3.5. Autoimmune deal milestone payments
• 3.6. Autoimmune deal royalty rates

Chapter 4 - Leading autoimmune dealmakers and deals

• 4.1. Introduction
• 4.2. Most active in autoimmune dealmaking
• 4.3. List of most active dealmakers in autoimmune
• 4.4. Top autoimmune deals by value

Chapter 5 - Autoimmune deal contract document directory

• 5.1. Introduction
• 5.2. Autoimmune partnering deals where contract document available

Chapter 6 - Autoimmune dealmaking by therapeutic target

• 6.1. Introduction
• 6.2. Deals by autoimmune therapeutic target
• Deal Directory
• Deal Directory - Autoimmune deals by company A-Z 2016 to 2025
• Deal Directory - Autoimmune deals by technology type 2016 to 2025
• Deal type definitions
• About Biopharma Research Ltd
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

TABLE OF FIGURES

• Figure 1: Autoimmune deals since 2016
• Figure 2: Autoimmune deals by deal type since 2016
• Figure 3: Autoimmune deals by industry sector since 2016
• Figure 4: Autoimmune deals by stage of development since 2016
• Figure 5: Autoimmune deals by technology type since 2016
• Figure 6: Autoimmune deals with a headline value
• Figure 7: Autoimmune deals with upfront payment values
• Figure 8: Autoimmune deals with milestone payment
• Figure 9: Autoimmune deals with royalty rates
• Figure 10: Active autoimmune dealmaking activity since 2016
• Figure 11: Top autoimmune deals by value since 2016